However, in the early treatment schedule, IL-2/S4B6 significantly prolonged median survival of CT26 tumor-bearing mice (by ∼40%) compared with control treatment and completely cured 1 out of 16 mice (figure 3C). The gene discussed is IL2; the disease is neoplasm.